Rupatadine - Pharmacology, clinical profile and safety of a new antihistamine with PAF-antagonizing quality;Rupatadin - Pharmakologie, klinische wirksamkeit und therapeutische sicherheit eines neuen antihistamins mit zusätzlicher, PAF- antagonisierender wirkung

Allergologie

Volumn 33, Issue 10, 2010, Pages 429-440

  Thorn, C ^a,b   Pfaar, O ^a,b   Hormann K ^a   Klimek, L ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Zentrum Für Rhinologie und Allergologie Wiesbaden   (Germany)

Author keywords

Allergic rhinitis; Allergy; Antihistamine; Chronic urticaria; PAF

Indexed keywords

HISTAMINE H1 RECEPTOR; RUPATADINE; THROMBOCYTE ACTIVATING FACTOR RECEPTOR;

DRUG EFFICACY; DRUG SAFETY; GERMANY; HEART ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; REVIEW;

EID: 78049335913     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: 10.5414/alp33429     Document Type: Review

References (53)

1. Aaaai. The allergy report. Aviable at: www.theallergyreport.com; 2008.
2. Barbanoj MJ, Garcia-Gea C, Morte A et al. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology. 2004; 50: 311-321.
3. 1 receptor dependent mechanism. Rev Rhinol. 2006; 6: 18.
4. Caballero R, Valenzuela C, Longobardo M et al. Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac kv1.5 channels. Br J Pharmacol. 1999; 128: 1071-1081.
5. Camelo-Nunes IC. New antihistamines: a critical view. J Pediatr (Rio J). 2006; 82: S173-S180.
6. Carvajal A, Macias D, Salado I et al. Heart rhythm disturbances associated with rupatadine: a case series from the Spanish and Portuguese pharmacovigilance systems. Clin Pharmacol Ther. 2009; 85: 481-484.
7. 1 antihistamines upon the cardiovascular system. J Investig Allergol Clin Immunol. 2006; 16 (Suppl 1): 13-23.
8. Di Leo E, Nettis E, Cassano N et al. Treatment of acquired cold urticaria with rupatadine. Allergy. 2009; 64: 1387-1388.
9. Dubertret L, Zalupca L, Cristodoulo T et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol. 2007; 17: 223-228.
10. Fantin S, Maspero J, Bisbal C et al. A 12-week placebo-controlled study of rupatadine 10mgonce daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis. Allergy. 2008; 63: 924-931.
11. Fite-Mora R. Torsade de pointes associated with rupatadine. Rev Esp Cardiol. 2009; 62: 330-331, author reply 332.
12. Gimenez-Arnau A, Izquierdo I, Maurer M. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo-controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol. 2009; 23: 1088-1091.
13. Gimenez-Arnau A, Pujol RM, Ianosi S et al. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study. Allergy. 2007; 62: 539-546.
14. Giral M, Balsa D, Ferrando R, Merlos M, Garcia-Rafanell J, Forn J. CNS activity profile of rupatadine fumarate, a new dual receptor antagonist of platelet-activating factor (PAF) and histamine. Allergy. 1998; 53: 131.
15. Giral M, Merlos M, Balsa D, Ferrando R, Garcia-Rafanell J, Forn J. Effects of rupatadine on cardiovascular profile in rats and guinea pigs: comparison with other nonsedating antihistamines. Allergy. 1997; 52: 44-45.
16. Grattan CE. Towards rationalizing the nomenclature and classification of urticaria: some guidance on guidelines. Clin Exp Allergy. 2007; 37: 625-626.
17. Guadano EM, Serra-Batlles J, Meseguer J, Castillo JA, De Molina M, Valero A. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy. 2004; 59: 766-771. (Pubitemid 38850353)
18. Holgate ST, Canonica GW, Simons FE et al. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy. 2003; 33: 1305-1324.
19. Hove-Madsen L, Llach A, Molina CE et al. The proarrhythmic antihistaminic drug terfenadine increases spontaneous calcium release in human atrial myocytes. Eur J Pharmacol. 2006; 553: 215-221. (Pubitemid 44779593)
20. Howarth PH, Salagean M, Dokic D. Allergic rhinitis: not purely a histamine-related disease. Allergy. 2000; 55 (Suppl 64): 7-16.
21. 1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc). 2003; 39: 451-468.
22. Izquierdo I, Paredes I, Lurigados C, Sospedra E, Cooper M, Thomas H. A dose ranging study of rupatadine fumarate in patients with seasonal allergic rhinitis. Allergy. 2000; 55: 275.
23. Keam SJ, Plosker GL. Rupatadine: a review of its use in the management of allergic disorders. Drugs. 2007; 67: 457-474.
24. Klimek L. Allergy. An increasing problem with far-reaching consequences. HNO. 2008; 56: 749.
25. Martinez-Cocera C, De Molina M, Marti-Guadan E, Pola J, Conde J, Borja J. Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. J lnvestig Allergol Clin Immunol. 2005; 15: 22-29.
26. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol. 2001; 108: S45-S53.
27. Merckle-Recordati-GmbH. Rupafin Fachinformation; 2008.
28. Merlos M, Balsa D, Giral M, Ferrando R, Ramis I, Forn J. Effect of topical rupatadine in experimental conjunctivitis in guinea pig: evaluation of ocular lesion. J Allergy Clin Immunol. 2001; 107 (Suppl 2): 310.
29. Merlos M, Giral M, Balsa D et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther. 1997; 280: 114-121.
30. Merlos M, Giral M, Balsa D, Ferrando R, Gracia- Raffanell J, Forn J. Rupatadine inhibits the eosinophil recruitment in BAL fluid of ovalbumin- sensitized guinea pigs. J Allergy Clin Immunol. 1998; 101: 281.
31. Metz M, Scholz E, Ferran M et al. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol. 2010; 104: 86-92.
32. Mullol J, Bousquet J, Bachert C et al. Rupatadine in allergic rhinitis and chronic urticaria. Allergy. 2008; 63 (Suppl 87): 5-28.
33. Nagai H, Teramachi H, Tuchiya T. Recent advances in the development of anti-allergic drugs. Allergol Int. 2006; 55: 35-42.
34. O'Donnell BF, Lawlor F, Simpson J et al. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997; 136: 197-201. (Pubitemid 27062719)
35. Perez I, De La Cruz G, Villa M, Iz-Quierdo I. Rupatadine in allergic rhinitis: pooled analysis of efficacy data. Allergy. 2002; 57: 245.
36. Pfaar O, Klimek L. Specific immunotherapy for allergic rhinitis. Current methods and innovative developments. HNO. 2008; 56: 764-775.
37. Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother. 2006; 7: 1989-2001.
38. Poonawalla T, Kelly B. Urticaria: a review. Am J Clin Dermatol. 2009; 10: 9-21.
39. Queralt M, Brazis P, MerlosMet al. In vitro inhibitory effect of rupatadine on histamine and TNF-alpha release from dispersed canine skin mast cells and the human mast cell line HMC-1. Inflamm Res. 2000; 49: 355-360.
40. Queralt M, Brazis P, Merlos M, Puigdemont A. Inhibitory effects of rupatadine on mast cell histamine release and skin wheal development induced by Ascaris suum in hypersensitive dogs. Drug Dev. Res. 1998; 44: 49-55.
41. Queralt M, Merlos M, Giral M, Puigdemont A. Dual effect of a new compound, rupatadine, on edema induced by platelet-activating factor and histamine in dogs: comparison with antihistamines and PAF antagonists. Drug Dev Res. 1996; 39: 12-18.
42. Quraishi SA, Davies MJ, Craig TJ. Inflammatory responses in allergic rhinitis: traditional approaches and novel treatment strategies. J AmOsteopath Assoc. 2004; 104: S7-S15.
43. Ramis I, Giral M, Ferrando R, Merlos M. Inhibition of PAF- and LTB4-induced human neutrophil chemotaxis by rupatadine using a new fluorescent chemotaxis assay. Allergy. 2000; 55: 94-95.
44. th EAACI Congress; 2006.
45. Roumestan CHC, Mathieu M, Bousquet J. Effects of rupatadine on inflammatory mediators and transcription factors: a comparsion with desloratardine and levocetrizine. Allergy Clin ImmunolInt. 2005; 17: 450.
46. 1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J lnvestig Allergol Clin Immunol. 2004; 14: 34-40.
47. Saloga J, Klimek L, Buhl R, Mann W, Knop J. Allergologie Handbuch. Stuttgart: Schattauer; 2005.
48. Strachan D, Sibbald B, Weiland S et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol. 1997; 8: 161-176.
49. Stuebner P, Horak F, Zieglmayer R et al. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol. 2006; 96: 37-44.
50. Valero A, Bartra J, Serrano C, Donado E, Gracia O, Izquierdo I. Rupatadine reduces nasal obstruction in allergen-induced rhinitis. Allergy. 2007; 62: 137-138.
51. Valero A, De La Torre F, Castillo JA et al. Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain. Drug Saf. 2009; 32: 33-42.
52. Vuurman E, Theunissen E, Van Oers A et al. Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. HumPsychopharmacol. 2007; 22: 289-297. (Pubitemid 47180390)
53. Zuberbier T, Bindslev-Jensen C, CanonicaWet al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy. 2006; 61: 316-320.